{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-067398","form_type":"8-K","ticker":"UNCY","cik":"0001766140","company_name":"Unicycive Therapeutics, Inc.","filed_at":"2023-08-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.160053+00:00","generated_at":"2026-06-11T09:31:18.815410+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Unicycive Q2 net loss $4.4M; OLC FDA feedback expected Fall 2023; UNI-494 Phase 1 ongoing","bullets":["Net loss of $4.4M ($0.29/share) in Q2 2023, up from $3.6M ($0.24) in Q2 2022 due to higher R&D and G&A costs.","Cash and equivalents totaled $18.8M as of June 30, 2023.","Positive OLC data published in Am J Nephrol: lowest daily dose volume vs five commercial phosphate binders.","Expects FDA alignment feedback in Fall 2023 for OLC program; NDA submission after that.","UNI-494 Phase 1 trial ongoing in UK; pre-IND meeting with FDA planned by year-end; IND expected in 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-067398","json":"https://secwatch.observer/filing/0001213900-23-067398.json","markdown":"https://secwatch.observer/filing/0001213900-23-067398.md","text":"https://secwatch.observer/filing/0001213900-23-067398.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1766140/000121390023067398/0001213900-23-067398-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1766140/000121390023067398/ea183515-8k_unicycive.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T09:31:18.815410+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4524f19f390409a9306ab744452625c479243fac","claim":"Unicycive Therapeutics, Inc. reported the second quarter ended June 30, 2023 results: net income $4.4 million, EPS $0.29 per share of common stock.","evidence_excerpt":"Net loss attributable to common stockholders for the quarter ended June 30, 2023 was $4.4 million, or $0.29 per share of common stock","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1766140/000121390023067398/0001213900-23-067398-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Net income","value":"$4.4 million"},{"label":"EPS","value":"$0.29 per share of common stock"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}